{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T11:31:03Z","timestamp":1792323063857,"version":"4.4.0"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100008089","name":"Fondazione Internazionale Menarini","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008089","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s13300-024-01550-5","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T07:01:53Z","timestamp":1712300513000},"page":"1099-1124","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["SGLT2 Inhibitors\u00a0\u2013 The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review"],"prefix":"10.1007","volume":"15","author":[{"given":"Samuel","family":"Seidu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki","family":"Alabraba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Newland-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Fernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Bain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Diggle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Kanumilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Milne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adie","family":"Viljoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2839-8404","authenticated-orcid":false,"given":"John P. H.","family":"Wilding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"key":"1550_CR1","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s13300-018-0471-8","volume":"9","author":"J Wilding","year":"2018","unstructured":"Wilding J, Fernando K, Milne N, Evans M, Ali A, Bain S, et al. SGLT2 inhibitors in type 2 diabetes management: key evidence and implications for clinical practice. Diabetes Ther. 2018;9:1757\u201373.","journal-title":"Diabetes Ther"},{"key":"1550_CR2","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s13300-019-0657-8","volume":"10","author":"A Ali","year":"2019","unstructured":"Ali A, Bain S, Hicks D, Newland Jones P, Patel DC, Evans M, et al. SGLT2 inhibitors: cardiovascular benefits beyond HbA1c-translating evidence into practice. Diabetes Ther. 2019;10:1595\u2013622.","journal-title":"Diabetes Ther"},{"key":"1550_CR3","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1007\/s13300-020-00930-x","volume":"11","author":"DC Wheeler","year":"2020","unstructured":"Wheeler DC, James J, Patel D, Viljoen A, Ali A, Evans M, et al. SGLT2 inhibitors: slowing of chronic kidney disease progression in type 2 diabetes. Diabetes Ther. 2020;11:2757\u201374.","journal-title":"Diabetes Ther"},{"key":"1550_CR4","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s13300-022-01228-w","volume":"13","author":"JPH Wilding","year":"2022","unstructured":"Wilding JPH, Evans M, Fernando K, Gorriz JL, Cebrian A, Diggle J, et al. The place and value of sodium-glucose cotransporter 2 inhibitors in the evolving treatment paradigm for type 2 diabetes mellitus: a narrative review. Diabetes Ther. 2022;13:847\u201372.","journal-title":"Diabetes Ther"},{"key":"1550_CR5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.diabet.2017.06.003","volume":"43","author":"G Reach","year":"2017","unstructured":"Reach G, Pechtner V, Gentilella R, Corcos A, Ceriello A. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab. 2017;43:501\u201311.","journal-title":"Diabetes Metab"},{"key":"1550_CR6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3390\/medicina59010182","volume":"59","author":"TH Almigbal","year":"2023","unstructured":"Almigbal TH, Alzarah SA, Aljanoubi FA, Alhafez NA, Aldawsari MR, Alghadeer ZY, et al. Clinical inertia in the management of type 2 diabetes mellitus: a systematic review. Medicina (Kaunas). 2023;59:182.","journal-title":"Medicina (Kaunas)"},{"key":"1550_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12933-020-01154-w","volume":"19","author":"G Schernthaner","year":"2020","unstructured":"Schernthaner G, Shehadeh N, Ametov AS, Bazarova AV, Ebrahimi F, Fasching P, et al. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc Diabetol. 2020;19:185.","journal-title":"Cardiovasc Diabetol"},{"key":"1550_CR8","unstructured":"National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. NICE guideline. NG28. 2022."},{"key":"1550_CR9","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","volume":"65","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycaemia in type 2 diabetes, 2022, a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65:1925\u201366.","journal-title":"Diabetologia"},{"key":"1550_CR10","unstructured":"IQVIA. Longitudinal prescription data: SGLT2 inhibitor prescribing data for England. 2023."},{"key":"1550_CR11","doi-asserted-by":"publisher","DOI":"10.1530\/EC-23-0005","volume":"12","author":"MC Thomas","year":"2023","unstructured":"Thomas MC, Neuen BL, Twigg SM, Cooper ME, Badve SV. SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review. Endocr Connect. 2023;12: e230005.","journal-title":"Endocr Connect"},{"key":"1550_CR12","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s13300-022-01242-y","volume":"13","author":"M Evans","year":"2022","unstructured":"Evans M, Morgan AR, Bain SC, Davies S, Dashora U, Sinha S, et al. Defining the role of SGLT2 inhibitors in primary care: time to think differently. Diabetes Ther. 2022;13:889\u2013911.","journal-title":"Diabetes Ther"},{"key":"1550_CR13","unstructured":"Alder A. United Kingdom Prospective Study (UKPDS) 44-year follow-up symposium. UKPDS perspective, legacy effects and 44-year follow-up data [Internet]. Hybrid 58th EASD Annual Meeting. 2022 [cited 2023 Dec 19]. https:\/\/www.easd.org\/media-centre\/#!resources\/ukpds-perspective-legacy-effects-and-44-year-follow-up-data. Accessed 14 Mar 2024"},{"key":"1550_CR14","unstructured":"Holman RR. United Kingdom Prospective Study (UKPDS) 44-year follow-up symposium. Clinical outcomes at 44 years: do the legacy effects persist? [Internet]. Hybrid 58th EASD Annual Meeting. 2022 [cited 2023 Dec 19]. https:\/\/www.easd.org\/media-centre\/#!resources\/clinical-outcomes-at-44-years-do-the-legacy-effects-persist. Accessed 14 Mar 2024"},{"key":"1550_CR15","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1007\/s13300-020-00926-7","volume":"11","author":"D Matthews","year":"2020","unstructured":"Matthews D, Del Prato S, Mohan V, Mathieu C, Vencio S, Chan JCN, et al. Insights from VERIFY: early combination therapy provides better glycaemic durability than a stepwise approach in newly diagnosed type 2 diabetes. Diabetes Ther. 2020;11:2465\u201376.","journal-title":"Diabetes Ther"},{"key":"1550_CR16","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012356","volume":"8","author":"D Giugliano","year":"2019","unstructured":"Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Esposito K. Glycemic control, preexisting cardiovascular disease, and risk of major cardiovascular events in patients with type 2 diabetes mellitus: systematic review with meta-analysis of cardiovascular outcome trials and intensive glucose control trials. J Am Heart Assoc. 2019;8: e012356.","journal-title":"J Am Heart Assoc"},{"key":"1550_CR17","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"1550_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"1550_CR19","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824","volume":"144","author":"M Packer","year":"2021","unstructured":"Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial. Circulation. 2021;144:1284\u201394.","journal-title":"Circulation"},{"key":"1550_CR20","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","volume":"143","author":"M Packer","year":"2021","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction. Circulation. 2021;143:326\u201336.","journal-title":"Circulation"},{"key":"1550_CR21","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295\u2013306.","journal-title":"N Engl J Med"},{"key":"1550_CR22","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1681\/ASN.2016030278","volume":"28","author":"HJL Heerspink","year":"2017","unstructured":"Heerspink HJL, Desai M, Jardine M, Balis D, Meininger G, Perkovic V. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol. 2017;28:368\u201375.","journal-title":"J Am Soc Nephrol"},{"key":"1550_CR23","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1111\/dom.14671","volume":"24","author":"JY Barraclough","year":"2022","unstructured":"Barraclough JY, Yu J, Figtree GA, Perkovic V, Heerspink HJL, Neuen BL, et al. Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: data from the CANVAS Program and CREDENCE trial. Diabetes Obes Metab. 2022;24:1072\u201383.","journal-title":"Diabetes Obes Metab"},{"key":"1550_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2022-003072","volume":"11","author":"A Gonzalez Perez","year":"2023","unstructured":"Gonzalez Perez A, Vizcaya D, S\u00e1ez ME, Lind M, Garcia Rodriguez LA. Cardiovascular and renal outcomes among patients with type 2 diabetes using SGLT2 inhibitors added to metformin: a population-based cohort study from the UK. BMJ Open Diabetes Res Care. 2023;11: e003072.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1550_CR25","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.3390\/ijms23073651","volume":"23","author":"T Salvatore","year":"2022","unstructured":"Salvatore T, Galiero R, Caturano A, Rinaldi L, Di Martino A, Albanese G, et al. An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. Int J Mol Sci. 2022;23:3651.","journal-title":"Int J Mol Sci"},{"key":"1550_CR26","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1111\/dom.15111","volume":"25","author":"AK Forbes","year":"2023","unstructured":"Forbes AK, Suckling RJ, Hinton W, Feher MD, Banerjee D, Cole NI, et al. Sodium-glucose cotransporter-2 inhibitors and kidney outcomes in real-world type 2 diabetes populations: a systematic review and meta-analysis of observational studies. Diabetes Obes Metab. 2023;25:2310\u201330.","journal-title":"Diabetes Obes Metab"},{"key":"1550_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000503919","volume":"10","author":"KB Lo","year":"2020","unstructured":"Lo KB, Gul F, Ram P, Kluger AY, Tecson KM, McCullough PA, et al. The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: a systematic review and meta-analysis. Cardiorenal Med. 2020;10:1\u201310.","journal-title":"Cardiorenal Med"},{"key":"1550_CR28","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"key":"1550_CR29","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383:1425\u201335.","journal-title":"N Engl J Med"},{"key":"1550_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31\u20139.","journal-title":"Lancet"},{"key":"1550_CR31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117\u201327.","journal-title":"N Engl J Med"},{"issue":"102","key":"1550_CR32","first-page":"S1","volume":"2022","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO","year":"2022","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO. clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;2022(102):S1-127.","journal-title":"Kidney Int"},{"key":"1550_CR33","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.pcd.2022.02.002","volume":"16","author":"S Seidu","year":"2022","unstructured":"Seidu S, Cos X, Brunton S, Harris SB, Jansson SPO, Mata-Cases M, et al. 2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care. Prim Care Diabetes. 2022;16:223\u201344.","journal-title":"Prim Care Diabetes"},{"key":"1550_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009417","volume":"6","author":"DS Shyangdan","year":"2016","unstructured":"Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2016;6: e009417.","journal-title":"BMJ Open"},{"key":"1550_CR35","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/dom.12670","volume":"18","author":"F Zaccardi","year":"2016","unstructured":"Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18:783\u201394.","journal-title":"Diabetes Obes Metab"},{"key":"1550_CR36","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium","year":"2022","unstructured":"Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400:1788\u2013801.","journal-title":"Lancet"},{"key":"1550_CR37","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12933-023-01937-x","volume":"22","author":"M Marassi","year":"2023","unstructured":"Marassi M, Fadini GP. The cardio-renal-metabolic connection: a review of the evidence. Cardiovasc Diabetol. 2023;22:195.","journal-title":"Cardiovasc Diabetol"},{"key":"1550_CR38","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/17446651.2023.2210673","volume":"18","author":"AJ Scheen","year":"2023","unstructured":"Scheen AJ. The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review. Expert Rev Endocrinol Metab. 2023;18:271\u201382.","journal-title":"Expert Rev Endocrinol Metab"},{"key":"1550_CR39","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s13300-023-01454-w","volume":"14","author":"D Chipayo-Gonzales","year":"2023","unstructured":"Chipayo-Gonzales D, Shabbir A, Vergara-Uzcategui C, Nombela-Franco L, Jimenez-Quevedo P, Gonzalo N, et al. Treatment with SGLT2 inhibitors in patients with diabetes mellitus and extensive coronary artery disease: mortality and cardiovascular outcomes. Diabetes Ther. 2023;14:1853\u201365.","journal-title":"Diabetes Ther"},{"key":"1550_CR40","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.diabres.2014.05.005","volume":"105","author":"WD Strain","year":"2014","unstructured":"Strain WD, Cos X, Hirst M, Vencio S, Mohan V, Vok\u00f3 Z, et al. Time to do more: addressing clinical inertia in the management of type 2 diabetes mellitus. Diabetes Res Clin Pract. 2014;105:302\u201312.","journal-title":"Diabetes Res Clin Pract"},{"key":"1550_CR41","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1111\/dom.15040","volume":"25","author":"P McEwan","year":"2023","unstructured":"McEwan P, Foos V, Martin B, Chen J, Evans M. Estimating the value of sodium-glucose cotransporter-2 inhibitors within the context of contemporary guidelines and the totality of evidence. Diabetes Obes Metab. 2023;25:1830\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"1550_CR42","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s00125-022-05832-0","volume":"66","author":"JI Morton","year":"2023","unstructured":"Morton JI, Marquina C, Shaw JE, Liew D, Polkinghorne KR, Ademi Z, et al. Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis. Diabetologia. 2023;66:642\u201356.","journal-title":"Diabetologia"},{"key":"1550_CR43","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11892-020-1292-5","volume":"20","author":"Y Yoshida","year":"2020","unstructured":"Yoshida Y, Cheng X, Shao H, Fonseca VA, Shi L. A systematic review of cost-effectiveness of sodium-glucose cotransporter inhibitors for type 2 diabetes. Curr Diab Rep. 2020;20:12.","journal-title":"Curr Diab Rep"},{"key":"1550_CR44","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1038\/s41598-019-40191-8","volume":"9","author":"KL Chin","year":"2019","unstructured":"Chin KL, Ofori-Asenso R, Si S, Hird TR, Magliano DJ, Zoungas S, et al. Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes. Sci Rep. 2019;9:3256.","journal-title":"Sci Rep"},{"key":"1550_CR45","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-054654","volume":"12","author":"S Hodgson","year":"2022","unstructured":"Hodgson S, Morgan-Harrisskitt J, Hounkpatin H, Stuart B, Dambha-Miller H. Primary care service utilisation and outcomes in type 2 diabetes: a longitudinal cohort analysis. BMJ Open. 2022;12: e054654.","journal-title":"BMJ Open"},{"key":"1550_CR46","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12916-019-1373-y","volume":"17","author":"M Nowakowska","year":"2019","unstructured":"Nowakowska M, Zghebi SS, Ashcroft DM, Buchan I, Chew-Graham C, Holt T, et al. The comorbidity burden of type 2 diabetes mellitus: patterns, clusters and predictions from a large English primary care cohort. BMC Med. 2019;17:145.","journal-title":"BMC Med"},{"key":"1550_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-033866","volume":"10","author":"SS Zghebi","year":"2020","unstructured":"Zghebi SS, Steinke DT, Rutter MK, Ashcroft DM. Eleven-year multimorbidity burden among 637 255 people with and without type 2 diabetes: a population-based study using primary care and linked hospitalisation data. BMJ Open. 2020;10: e033866.","journal-title":"BMJ Open"},{"key":"1550_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100666","volume":"31","author":"A Ceriello","year":"2023","unstructured":"Ceriello A, Lucisano G, Prattichizzo F, La Grotta R, Frig\u00e9 C, De Cosmo S, et al. The legacy effect of hyperglycemia and early use of SGLT-2 inhibitors: a cohort study with newly-diagnosed people with type 2 diabetes. Lancet Region Health Eur. 2023;31: 100666.","journal-title":"Lancet Region Health Eur"},{"key":"1550_CR49","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"M Kosiborod","year":"2017","unstructured":"Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017;136:249\u201359.","journal-title":"Circulation"},{"key":"1550_CR50","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12933-021-01345-z","volume":"20","author":"K Khunti","year":"2021","unstructured":"Khunti K, Kosiborod M, Kim DJ, Kohsaka S, Lam CSP, Goh S-Y, et al. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. Cardiovasc Diabetol. 2021;20:159.","journal-title":"Cardiovasc Diabetol"},{"key":"1550_CR51","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","volume":"8","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Karasik A, Thuresson M, Melzer-Cohen C, Chodick G, Khunti K, et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol. 2020;8:27\u201335.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1550_CR52","doi-asserted-by":"publisher","first-page":"4248","DOI":"10.3390\/jcm12134248","volume":"12","author":"JJ Gorgojo-Martinez","year":"2023","unstructured":"Gorgojo-Martinez JJ, Ferreira-Ocampo PJ, Gald\u00f3n Sanz-Pastor A, C\u00e1rdenas-Salas J, Ant\u00f3n-Bravo T, Brito-Sanfiel M, et al. Effectiveness and tolerability of the intensification of canagliflozin dose from 100 mg to 300 mg daily in patients with type 2 diabetes in real life: the INTENSIFY study. J Clin Med. 2023;12:4248.","journal-title":"J Clin Med"},{"key":"1550_CR53","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"1550_CR54","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1002\/ehf2.13236","volume":"8","author":"J Yu","year":"2021","unstructured":"Yu J, Arnott C, Neuen BL, Heersprink HL, Mahaffey KW, Cannon CP, et al. Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program. ESC Heart Fail. 2021;8:1482\u201393.","journal-title":"ESC Heart Fail"},{"key":"1550_CR55","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323\u201334.","journal-title":"N Engl J Med"},{"key":"1550_CR56","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE\u2013TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7:606\u201317.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1550_CR57","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/00325481.2016.1169894","volume":"128","author":"L Blonde","year":"2016","unstructured":"Blonde L, Stenl\u00f6f K, Fung A, Xie J, Canovatchel W, Meininger G. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgrad Med. 2016;128:371\u201380.","journal-title":"Postgrad Med"},{"key":"1550_CR58","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1210\/jc.2011-2260","volume":"97","author":"J Bolinder","year":"2012","unstructured":"Bolinder J, Ljunggren \u00d6, Kullberg J, Johansson L, Wilding J, Langkilde AM, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020\u201331.","journal-title":"J Clin Endocrinol Metab"},{"key":"1550_CR59","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/1479164115616901","volume":"13","author":"IJ Neeland","year":"2016","unstructured":"Neeland IJ, McGuire DK, Chilton R, Crowe S, Lund SS, Woerle HJ, et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2016;13:119\u201326.","journal-title":"Diab Vasc Dis Res"},{"key":"1550_CR60","doi-asserted-by":"publisher","first-page":"216","DOI":"10.4183\/aeb.2022.216","volume":"18","author":"K Pratama","year":"2022","unstructured":"Pratama K. Weight loss effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with obesity without diabetes: a systematic review. Acta Endocrinol (Bucharest). 2022;18:216\u201324.","journal-title":"Acta Endocrinol (Bucharest)"},{"key":"1550_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2023.108628","volume":"37","author":"R Weingold","year":"2023","unstructured":"Weingold R, Zinman B, Mattheus M, Ofstad AP, Steubl D, Wanner C, et al. Shifts in KDIGO CKD risk groups with empagliflozin: kidney-protection from SGLT2 inhibition across the spectrum of risk. J Diabetes Complic. 2023;37: 108628.","journal-title":"J Diabetes Complic"},{"key":"1550_CR62","unstructured":"UK Kidney Association. UK Kidney Association clinical practice guideline: Sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease [Internet]. 2021 [cited 2023 Dec 19]. https:\/\/ukkidney.org\/health-professionals\/guidelines\/ukka-clinical-practice-guideline-sodium-glucose-co-transporter-2. Accessed 14 Mar 2024"},{"key":"1550_CR63","unstructured":"A. Menarini Farmaceutica Internazionale SRL. Invokana 300 mg film-coated tablets. Summary of product characteristics [Internet]. 2021 [cited 2023 Dec 19]. https:\/\/www.medicines.org.uk\/emc\/product\/11409. Accessed 14 Mar 2024"},{"key":"1550_CR64","unstructured":"Boehringer Ingelheim Limited. Jardiance 25 mg film-coated tablets. Summary of product characteristics [Internet]. 2023 [cited 2023 Dec 19]. https:\/\/www.medicines.org.uk\/emc\/product\/7703\/smpc. Accessed 14 Mar 2024"},{"key":"1550_CR65","unstructured":"AstraZeneca UK Limited. Forxiga 10 mg film-coated tablets. Summary of product characteristics [Internet]. 2022 [cited 2023 Dec 19]. https:\/\/www.medicines.org.uk\/emc\/product\/7607\/smpc. Accessed 14 Mar 2024"},{"key":"1550_CR66","unstructured":"Merck Sharp & Dohme (UK) Limited. Steglatro 15 mg film-coated tablets. Summary of product characteristics [Internet]. 2022 [cited 2023 Dec 19]. https:\/\/www.medicines.org.uk\/emc\/product\/10099\/smpc. Accessed 14 Mar 2024"},{"key":"1550_CR67","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599\u2013726.","journal-title":"Eur Heart J"},{"key":"1550_CR68","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255\u2013323.","journal-title":"Eur Heart J"},{"key":"1550_CR69","doi-asserted-by":"publisher","first-page":"afac201","DOI":"10.1093\/ageing\/afac201","volume":"51","author":"M Evans","year":"2022","unstructured":"Evans M, Morgan AR, Davies S, Beba H, Strain WD. The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus. Age Ageing. 2022;51:afac201.","journal-title":"Age Ageing"},{"key":"1550_CR70","unstructured":"NHS Digital. National Diabetes Audit. Young people with Type 2 diabetes, 2019\u201320 [Internet]. 2021 [cited 2023 Jul 26]. https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/national-diabetes-audit\/young-people-with-type-2-diabetes-2019--20#top. Accessed 14 Mar 2024"},{"key":"1550_CR71","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa2100165","volume":"385","author":"P Bjornstad","year":"2021","unstructured":"TODAY Study Group, Bjornstad P, Drews KL, Caprio S, Gubitosi-Klug R, Nathan DM, et al. Long-term complications in youth-onset type 2 diabetes. N Engl J Med. 2021;385:416\u201326.","journal-title":"N Engl J Med"},{"key":"1550_CR72","unstructured":"ClinRisk Ltd. QRISK\u00ae3-lifetime cardiovascular risk calculator [Internet]. 2023 [cited 2023 Jul 26]. https:\/\/qrisk.org\/lifetime. Accessed 14 Mar 2024"},{"key":"1550_CR73","unstructured":"ClinRisk Ltd. Welcome to the QRISK\u00ae3-2018 risk calculator [Internet]. [cited 2023 Aug 29]. https:\/\/www.qrisk.org\/. Accessed 14 Mar 2024"},{"key":"1550_CR74","unstructured":"National Institute for Health and Care Excellence. Putting NICE guidance in to Practice. Resource impact report: type 2 diabetes in adults: management (update) [Internet]. 2022 [cited 2023 Aug 4]. https:\/\/www.nice.org.uk\/guidance\/ng28\/resources\/resource-impact-report-type-2-diabetes-and-cardiovascular-risk-update-pdf-10958006557. Accessed 14 Mar 2024"},{"key":"1550_CR75","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1001\/jamacardio.2023.1090","volume":"8","author":"J Butler","year":"2023","unstructured":"Butler J, Usman MS, Filippatos G, Ferreira JP, B\u00f6hm M, Brueckmann M, et al. Safety and efficacy of empagliflozin and diuretic use in patients with heart failure and preserved ejection fraction. JAMA Cardiol. 2023;8:640.","journal-title":"JAMA Cardiol"},{"key":"1550_CR76","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jchf.2020.11.009","volume":"9","author":"L Shen","year":"2021","unstructured":"Shen L, Kristensen SL, Bengtsson O, B\u00f6hm M, de Boer RA, Docherty KF, et al. Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF. JACC Heart Fail. 2021;9:254\u201364.","journal-title":"JACC Heart Fail"},{"key":"1550_CR77","first-page":"152","volume":"29","author":"SK Peasah","year":"2023","unstructured":"Peasah SK, Huang Y, Palli SR, Swart EC, Donato BM, Pimple P, et al. Real-world impact of empagliflozin on total cost of care in adults with type 2 diabetes: Results from an outcomes-based agreement. J Manag Care Spec Pharm. 2023;29:152\u201360.","journal-title":"J Manag Care Spec Pharm"},{"key":"1550_CR78","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.7326\/M21-2941","volume":"175","author":"JG Choi","year":"2022","unstructured":"Choi JG, Winn AN, Skandari MR, Franco MI, Staab EM, Alexander J, et al. First-line therapy for type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a cost-effectiveness study. Ann Intern Med. 2022;175:1392\u2013400.","journal-title":"Ann Intern Med"},{"key":"1550_CR79","unstructured":"National Institute for Health and Care Excellence. Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes. Technology appraisal guidance [TA390] [Internet]. 2016 [cited 2024 Jan 17]. https:\/\/www.nice.org.uk\/guidance\/ta390. Accessed 14 Mar 2024"},{"key":"1550_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2020.107813","volume":"35","author":"N Kanumilli","year":"2021","unstructured":"Kanumilli N, Brunton S, Cos X, Deed G, Kushner P, Lin P, et al. Global survey investigating causes of treatment inertia in type 2 diabetes cardiorenal risk management. J Diabetes Complic. 2021;35: 107813.","journal-title":"J Diabetes Complic"},{"key":"1550_CR81","unstructured":"Medicines and Healthcare products Regulatory Agency. SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes) [Internet]. 2017 [cited 2023 Dec 19]. https:\/\/www.gov.uk\/drug-safety-update\/sglt2-inhibitors-updated-advice-on-increased-risk-of-lower-limb-amputation-mainly-toes#:~:text=Drug%20Safety%20Update-,SGLT2%20inhibitors%3A%20updated%20advice%20on%20increased%20risk%20of%20lower%2Dlimb,may%20be%20a%20class%20effect. Accessed 14 Mar 2024"},{"key":"1550_CR82","unstructured":"Medicines and Healthcare products Regulatory Agency. SGLT2 inhibitors: reports of Fournier\u2019s gangrene (necrotising fasciitis of the genitalia or perineum) [Internet]. 2019 [cited 2023 Aug 7]. https:\/\/www.gov.uk\/drug-safety-update\/sglt2-inhibitors-reports-of-fournier-s-gangrene-necrotising-fasciitis-of-the-genitalia-or-perineum. Accessed 14 Mar 2024"},{"key":"1550_CR83","first-page":"9","volume":"25","author":"P Brown","year":"2023","unstructured":"Brown P. Need to know guide: SGLT2 inhibitor indications, doses and licences (updated 2023). Diabetes Prim Care. 2023;25:9\u201310.","journal-title":"Diabetes Prim Care."},{"key":"1550_CR84","first-page":"49","volume":"22","author":"J Diggle","year":"2020","unstructured":"Diggle J. Ketones and diabetes. Diabetes Prim Care. 2020;22:49\u201350.","journal-title":"Diabetes Prim Care"},{"key":"1550_CR85","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.xkme.2019.12.006","volume":"2","author":"KM Wang","year":"2020","unstructured":"Wang KM, Isom RT. SGLT2 inhibitor-induced euglycemic diabetic ketoacidosis: a case report. Kidney Med. 2020;2:218\u201321.","journal-title":"Kidney Med"},{"key":"1550_CR86","first-page":"1","volume":"47","author":"MM Umapathysivam","year":"2023","unstructured":"Umapathysivam MM, Gunton J, Stranks SN, Jesudason D. Euglycemic ketoacidosis in two patients without diabetes after introduction of sodium-glucose cotransporter 2 inhibitor for heart failure with reduced ejection fraction. Diabetes Care. 2023;47:1\u20134.","journal-title":"Diabetes Care"},{"key":"1550_CR87","first-page":"113","volume":"25","author":"P Brown","year":"2023","unstructured":"Brown P. How to use SGLT2 inhibitors safely and effectively. Diabetes Prim Care. 2023;25:113\u20135.","journal-title":"Diabetes Prim Care"},{"key":"1550_CR88","doi-asserted-by":"publisher","first-page":"958","DOI":"10.5005\/jp-journals-10071-23929","volume":"25","author":"S Vadi","year":"2021","unstructured":"Vadi S, Lad V, Kapoor D. Perioperative implication of sodium-glucose cotransporter-2 inhibitor in a patient following major surgery. Indian J Crit Care Med. 2021;25:958\u20139.","journal-title":"Indian J Crit Care Med"},{"key":"1550_CR89","unstructured":"Kumar S, Bhavnani SP, Goyal P, Rich MW, Krishnaswami A. Preoperative cessation of SGLT2i [Internet]. American College of Cardiology. 2022 [cited 2023 Aug 14]. https:\/\/www.acc.org\/Latest-in-Cardiology\/Articles\/2022\/10\/07\/17\/21\/Preoperative-Cessation-of-SGLT2i. Accessed 14 Mar 2024"},{"key":"1550_CR90","doi-asserted-by":"publisher","first-page":"248","DOI":"10.7326\/M18-3136","volume":"171","author":"CV Dave","year":"2019","unstructured":"Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium\u2013glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections. Ann Intern Med. 2019;171:248\u201356.","journal-title":"Ann Intern Med"},{"key":"1550_CR91","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41574-019-0275-6","volume":"15","author":"J Wilding","year":"2019","unstructured":"Wilding J. SGLT2 inhibitors and urinary tract infections. Nat Rev Endocrinol. 2019;15:687\u20138.","journal-title":"Nat Rev Endocrinol"},{"key":"1550_CR92","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1111\/dom.15091","volume":"25","author":"A Kang","year":"2023","unstructured":"Kang A, Smyth B, Neuen BL, Heerspink HJL, Di Tanna GL, Zhang H, et al. The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: a pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials. Diabetes Obes Metab. 2023;25:2151\u201362.","journal-title":"Diabetes Obes Metab"},{"key":"1550_CR93","doi-asserted-by":"publisher","first-page":"165","DOI":"10.4103\/ijem.IJEM_614_18","volume":"23","author":"AS Dass","year":"2019","unstructured":"Dass AS, Immaculate G, Bhattacharyya A. Fournier\u2019s gangrene and sodium-glucose co-transporter 2 (SGLT2) inhibitors: our experience. Indian J Endocrinol Metab. 2019;23:165\u20136.","journal-title":"Indian J Endocrinol Metab"},{"key":"1550_CR94","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-000985","volume":"8","author":"JY Yang","year":"2020","unstructured":"Yang JY, Wang T, Pate V, Buse JB, St\u00fcrmer T. Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier\u2019s gangrene. BMJ Open Diabetes Res Care. 2020;8: e000985.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1550_CR95","volume":"14","author":"T Chowdhury","year":"2022","unstructured":"Chowdhury T, Gousy N, Bellamkonda A, Dutta J, Zaman CF, Zakia UB, et al. Fournier\u2019s Gangrene: a coexistence or consanguinity of SGLT-2 inhibitor therapy. Cureus. 2022;14: e27773.","journal-title":"Cureus"},{"key":"1550_CR96","unstructured":"National Institute for Health and Care Excellence. Clinical Knowledge Summary\u2014diabetes type 2 [Internet]. 2023 [cited 2023 Dec 19]. https:\/\/cks.nice.org.uk\/topics\/diabetes-type-2\/. Accessed 14 Mar 2024"},{"key":"1550_CR97","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3266","volume":"36","author":"NC Schaper","year":"2020","unstructured":"Schaper NC, Netten JJ, Apelqvist J, Bus SA, Hinchliffe RJ, Lipsky BA. Practical Guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update). Diabetes Metab Res Rev. 2020;36: e3266.","journal-title":"Diabetes Metab Res Rev"},{"key":"1550_CR98","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000520903","volume":"107","author":"RM See","year":"2022","unstructured":"See RM, Teo YN, Teo YH, Syn NL, Yip ASY, Leong S, et al. Effects of sodium-glucose cotransporter 2 on amputation events: a systematic review and meta-analysis of randomized-controlled trials. Pharmacology. 2022;107:123\u201330.","journal-title":"Pharmacology"},{"key":"1550_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.deman.2022.100054","volume":"6","author":"AJ Scheen","year":"2022","unstructured":"Scheen AJ. Lower-limb amputations in patients treated with SGLT2 inhibitors versus DPP-4 inhibitors: a meta-analysis of observational studies. Diabetes Epidemiol Manag. 2022;6: 100054.","journal-title":"Diabetes Epidemiol Manag"},{"key":"1550_CR100","first-page":"JDN144","volume":"24","author":"N Baker","year":"2020","unstructured":"Baker N. Diabetic foot care: a guide for non-specialists. J Diabetes Nurs. 2020;24:JDN144.","journal-title":"J Diabetes Nurs"},{"key":"1550_CR101","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s13300-021-01035-9","volume":"12","author":"WD Strain","year":"2021","unstructured":"Strain WD, Down S, Brown P, Puttanna A, Sinclair A. Diabetes and frailty: an expert consensus statement on the management of older adults with type 2 diabetes. Diabetes Ther. 2021;12:1227\u201347.","journal-title":"Diabetes Ther"},{"key":"1550_CR102","doi-asserted-by":"publisher","first-page":"147916412095362","DOI":"10.1177\/1479164120953625","volume":"17","author":"X Rong","year":"2020","unstructured":"Rong X, Li X, Gou Q, Liu K, Chen X. Risk of orthostatic hypotension associated with sodium-glucose cotransporter-2 inhibitor treatment: a meta-analysis of randomized controlled trials. Diab Vasc Dis Res. 2020;17:147916412095362.","journal-title":"Diab Vasc Dis Res"},{"key":"1550_CR103","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1161\/CIRCULATIONAHA.120.047077","volume":"142","author":"AM Jackson","year":"2020","unstructured":"Jackson AM, Dewan P, Anand IS, B\u011blohl\u00e1vek J, Bengtsson O, de Boer RA, et al. Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF. Circulation. 2020;142:1040\u201354.","journal-title":"Circulation"},{"key":"1550_CR104","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejim.2022.03.031","volume":"100","author":"CC van Ruiten","year":"2022","unstructured":"van Ruiten CC, Hesp AC, van Raalte DH. Sodium glucose cotransporter-2 inhibitors protect the cardiorenal axis: update on recent mechanistic insights related to kidney physiology. Eur J Intern Med. 2022;100:13\u201320.","journal-title":"Eur J Intern Med"},{"key":"1550_CR105","doi-asserted-by":"publisher","first-page":"742","DOI":"10.34067\/KID.0000412021","volume":"2","author":"D Lam","year":"2021","unstructured":"Lam D, Shaikh A. Real-life prescribing of SGLT2 inhibitors: how to handle the other medications, including glucose-lowering drugs and diuretics. Kidney360. 2021;2:742\u20136.","journal-title":"Kidney360"},{"key":"1550_CR106","doi-asserted-by":"publisher","DOI":"10.33590\/emjnephrol\/22-00080","author":"H Sawaf","year":"2022","unstructured":"Sawaf H, Qaz M, Ismail J, Mehdi A. The renal effects of SGLT2 inhibitors. EMJ Nephrol. 2022. https:\/\/doi.org\/10.33590\/emjnephrol\/22-00080.","journal-title":"EMJ Nephrol."},{"key":"1550_CR107","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s13300-015-0150-y","volume":"7","author":"Y Yavin","year":"2016","unstructured":"Yavin Y, Mansfield TA, Ptaszynska A, Johnsson K, Parikh S, Johnsson E. Effect of the SGLT2 inhibitor dapagliflozin on potassium levels in patients with type 2 diabetes mellitus: a pooled analysis. Diabetes Ther. 2016;7:125\u201337.","journal-title":"Diabetes Ther"},{"key":"1550_CR108","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","volume":"145","author":"BL Neuen","year":"2022","unstructured":"Neuen BL, Oshima M, Agarwal R, Arnott C, Cherney DZ, Edwards R, et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation. 2022;145:1460\u201370.","journal-title":"Circulation"},{"key":"1550_CR109","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.800490","author":"J Tang","year":"2022","unstructured":"Tang J, Ye L, Yan Q, Zhang X, Wang L. Effects of sodium-glucose cotransporter 2 inhibitors on water and sodium metabolism. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.800490.\u00a0Accessed 14 Mar 2024","journal-title":"Front Pharmacol"},{"key":"1550_CR110","doi-asserted-by":"publisher","first-page":"4891","DOI":"10.1093\/eurheartj\/ehab497","volume":"42","author":"BL Neuen","year":"2021","unstructured":"Neuen BL, Oshima M, Perkovic V, Agarwal R, Arnott C, Bakris G, et al. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. Eur Heart J. 2021;42:4891\u2013901.","journal-title":"Eur Heart J"},{"key":"1550_CR111","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jchf.2020.12.009","volume":"9","author":"F Zannad","year":"2021","unstructured":"Zannad F, Rossignol P. Mineralocorticoid receptor antagonists and SGLT2 inhibitor therapy: the best of both worlds in HFrEF. JACC Heart Fail. 2021;9:265\u20137.","journal-title":"JACC Heart Fail"},{"key":"1550_CR112","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1111\/dom.14801","volume":"24","author":"S Yang","year":"2022","unstructured":"Yang S, Zhao L, Mi Y, He W. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: a systematic review and network meta-analysis. Diabetes Obes Metab. 2022;24:2159\u201368.","journal-title":"Diabetes Obes Metab"},{"key":"1550_CR113","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12933-021-01344-0","volume":"20","author":"O Mosenzon","year":"2021","unstructured":"Mosenzon O, Alguwaihes A, Leon JLA, Bayram F, Darmon P, Davis TME, et al. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc Diabetol. 2021;20:154.","journal-title":"Cardiovasc Diabetol"},{"key":"1550_CR114","unstructured":"National Institute for Health and Care Excellence. Finerenone for treating chronic kidney disease in type 2 diabetes. Technology appraisal guidance. TA877 [Internet]. 2023 [cited 2023 Dec 19]. www.nice.org.uk\/guidance\/ta877. Accessed 14 Mar 2024"},{"key":"1550_CR115","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/dom.14559","volume":"24","author":"JP Ferreira","year":"2022","unstructured":"Ferreira JP, Inzucchi SE, Mattheus M, Meinicke T, Steubl D, Wanner C, et al. Empagliflozin and uric acid metabolism in diabetes: a post hoc analysis of the EMPA-REG OUTCOME trial. Diabetes Obes Metab. 2022;24:135\u201341.","journal-title":"Diabetes Obes Metab"},{"key":"1550_CR116","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.1016\/S2665-9913(19)30078-5","volume":"1","author":"J Li","year":"2019","unstructured":"Li J, Badve SV, Zhou Z, Rodgers A, Day R, Oh R, et al. The effects of canagliflozin on gout in type 2 diabetes: A post-hoc analysis of the CANVAS Program. Lancet Rheumatol. 2019;1:e220\u20138.","journal-title":"Lancet Rheumatol"},{"key":"1550_CR117","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/pds.5252","volume":"30","author":"LC Lund","year":"2021","unstructured":"Lund LC, H\u00f8jlund M, Henriksen DP, Hallas J, Kristensen KB. Sodium-glucose cotransporter-2 inhibitors and the risk of gout: a Danish population-based cohort study and symmetry analysis. Pharmacoepidemiol Drug Saf. 2021;30:1391\u20135.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1550_CR118","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1093\/rheumatology\/keac509","volume":"62","author":"J Zhou","year":"2023","unstructured":"Zhou J, Liu X, Chou OH-I, Li L, Lee S, Wong WT, et al. Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes. Rheumatology (Oxford). 2023;62:1501\u201310.","journal-title":"Rheumatology (Oxford)"},{"key":"1550_CR119","doi-asserted-by":"publisher","first-page":"186","DOI":"10.7326\/M19-2610","volume":"172","author":"M Fralick","year":"2020","unstructured":"Fralick M, Chen SK, Patorno E, Kim SC. Assessing the risk for gout with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study. Ann Intern Med. 2020;172:186\u201394.","journal-title":"Ann Intern Med"},{"key":"1550_CR120","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.30885","volume":"6","author":"J Wei","year":"2023","unstructured":"Wei J, Choi HK, Dalbeth N, Li X, Li C, Zeng C, et al. Gout flares and mortality after sodium-glucose cotransporter-2 inhibitor treatment for gout and type 2 diabetes. JAMA Netw Open. 2023;6: e2330885.","journal-title":"JAMA Netw Open"},{"key":"1550_CR121","first-page":"47","volume":"22","author":"S Down","year":"2020","unstructured":"Down S. How to advise on sick day rules. Diabetes Prim Care. 2020;22:47\u20138.","journal-title":"Diabetes Prim Care"},{"key":"1550_CR122","unstructured":"Fernando K. Comparison of ADA\/EASD and NICE Recommendations on the Pharmacological Management of Type 2 Diabetes In Adults [Internet]. Medscape. 2022 [cited 2023 Dec 19]. https:\/\/www.medscape.co.uk\/viewarticle\/primary-care-hacks-comparison-ada-easd-and-nice-2022a10024zc. Accessed 14 Mar 2024"},{"key":"1550_CR123","doi-asserted-by":"publisher","first-page":"204","DOI":"10.7861\/clinmed.2021-0045","volume":"21","author":"U Dashora","year":"2021","unstructured":"Dashora U, Gregory R, Winocour P, Dhatariya K, Rowles S, Macklin A, et al. Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations for non-diabetes specialists on the use of sodium glucose co-transporter 2 inhibitors in people with type 2 diabetes (January 2021). Clin Med (Lond). 2021;21:204\u201310.","journal-title":"Clin Med (Lond)"},{"key":"1550_CR124","unstructured":"Diabetes UK. Diabetes when you\u2019re unwell [Internet]. [cited 2023 Dec 19]. https:\/\/www.diabetes.org.uk\/guide-to-diabetes\/life-with-diabetes\/illness. Accessed 14 Mar 2024"},{"key":"1550_CR125","unstructured":"International Diabetes Federation, Diabetes and Ramadan (DAR) International Alliance. Diabetes and Ramadan: Practical guidelines [Internet]. 2021 [cited 2023 Dec 19]. https:\/\/dar-safa-storage-bahrain.s3.me-south-1.amazonaws.com\/IDF_Da_R_Practical_Guidelines_2021_web_166f7cbf4f.pdf. Accessed 14 Mar 2024"},{"key":"1550_CR126","unstructured":"Hanif W, Patel V, Ali S, Karamat A, Hassanein M, Syed A, et al. The South Asian Health Foundation (UK) Guidelines for managing diabetes during Ramadan: 2020 Update [Internet]. 2020 [cited 2023 Dec 19]. https:\/\/static1.squarespace.com\/static\/5944e54ab3db2b94bb077ceb\/t\/5e847ebf2c6ec1680158c373\/1585741505374\/Ramadan+Guidelines+Update.pdf. Accessed 14 Mar 2024"},{"key":"1550_CR127","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/ejhf.2220","volume":"23","author":"P Pellicori","year":"2021","unstructured":"Pellicori P, Fitchett D, Kosiborod MN, Ofstad AP, Seman L, Zinman B, et al. Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial. Eur J Heart Fail. 2021;23:1085\u201393.","journal-title":"Eur J Heart Fail"},{"key":"1550_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106396","volume":"183","author":"ME Lunati","year":"2022","unstructured":"Lunati ME, Cimino V, Gandolfi A, Trevisan M, Montefusco L, Pastore I, et al. SGLT2-inhibitors are effective and safe in the elderly: the SOLD study. Pharmacol Res. 2022;183: 106396.","journal-title":"Pharmacol Res"},{"key":"1550_CR129","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1161\/CIRCULATIONAHA.122.061754","volume":"146","author":"JH Butt","year":"2022","unstructured":"Butt JH, Jhund PS, Belohl\u00e1vek J, de Boer RA, Chiang C-E, Desai AS, et al. Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial. Circulation. 2022;146:1210\u201324.","journal-title":"Circulation"},{"key":"1550_CR130","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12933-023-01743-5","volume":"22","author":"A Goldman","year":"2023","unstructured":"Goldman A, Fishman B, Twig G, Raschi E, Cukierman-Yaffe T, Moshkovits Y, et al. The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (\u2265 75 years): a retrospective, pharmacovigilance study. Cardiovasc Diabetol. 2023;22:16.","journal-title":"Cardiovasc Diabetol"},{"key":"1550_CR131","unstructured":"TREND Diabetes. Something you need to know: how to reduce your risk of genital fungal infection [Internet]. 2023 [cited 2023 Dec 19]. https:\/\/trenddiabetes.online\/portfolio\/something-you-need-to-know-how-to-reduce-you-risk-of-genital-fungal-infection\/. Accessed 14 Mar 2024"},{"key":"1550_CR132","unstructured":"Diabetes UK. What is DKA (diabetic ketoacidosis)? [Internet]. [cited 2023 Dec 19]. https:\/\/www.diabetes.org.uk\/guide-to-diabetes\/complications\/diabetic_ketoacidosis. Accessed 14 Mar 2024"},{"key":"1550_CR133","unstructured":"TREND Diabetes. Type 2 diabetes and ketoacidosis [Internet]. [cited 2023 Aug 10]. https:\/\/trenddiabetes.online\/wp-content\/uploads\/2022\/03\/A5_DKA_TREND.pdf. Accessed 14 Mar 2024"},{"key":"1550_CR134","unstructured":"TREND Diabetes. What to do when you are ill [Internet]. 2022 [cited 2023 Dec 19]. https:\/\/trenddiabetes.online\/wp-content\/uploads\/2020\/03\/A5_T2Illness_TREND_FINAL.pdf. Accessed 14 Mar 2024"},{"key":"1550_CR135","unstructured":"TREND Diabetes. Looking after your feet when you have diabetes [Internet]. 2023 [cited 2023 Dec 19]. https:\/\/trenddiabetes.online\/portfolio\/looking-after-your-feet-when-you-have-diabetes\/. Accessed 14 Mar 2024"},{"key":"1550_CR136","unstructured":"Centre for Perioperative Care. Guideline for perioperative care for people with diabetes mellitus undergoing elective and emergency surgery [Internet]. 2022 [cited 2023 Dec 19]. https:\/\/cpoc.org.uk\/sites\/cpoc\/files\/documents\/2022-12\/CPOC-Diabetes-Guideline-Updated2022.pdf. Accessed 14 Mar 2024"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-024-01550-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-024-01550-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-024-01550-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:02:27Z","timestamp":1714003347000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-024-01550-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":136,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1550"],"URL":"https:\/\/doi.org\/10.1007\/s13300-024-01550-5","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,5]]},"assertion":[{"value":"19 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Samuel Seidu: speaker honoraria: AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, MSD, Abbott, Novo Nordisk, SB Communications, OmniaMed, Roche, Napp, NB Medical, Amgen; advisory board honoraria: AstraZeneca, Lilly, Boehringer Ingelheim, Janssen, Abbott, MSD, Novo Nordisk, Takeda, Sanofi; educational grants: Boehringer Ingelheim, Lilly, Novo Nordisk, Takeda; conference registration and subsistence: Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk, Abbott, Takeda. Vicki Alabraba: speaker\/advisory board fees: Dexcom, Napp, Roche, AstraZeneca, Eli Lilly, Boehringer Ingelheim, & Novo Nordisk; education grant: Menarini. Sarah Davies: speaker\/advisory board fees: Abbott, Amarin, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Daiichi Sankyo, Lilly, Menarini, Novo Nordisk, Roche. Philip Newland-Jones: sponsorship for education events, undertaken research for, or fees for educational speaking: Abbott, AstraZeneca, Boehringer Ingelheim, Sanofi, Eli Lilly, Novo Nordisk, LifeScan, MSD, Menarini, Mylan, Napp, Servier and Takeda. Kevin Fernando: speaker and advisory board honoraria from all current manufacturers of SGLT2is. Stephen Bain: personal fees: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, Roche & Sanofi-Aventis.\u00a0Stephen Bain\u00a0is an Editorial Board member\u00a0of Diabetes Therapy and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Jane Diggle: funding for provision of educational sessions and documents, and for attending advisory boards: Abbott, Bayer, AstraZeneca, Boehringer Ingelheim Eli Lilly, Menarini, Novo Nordisk, Roche, Sanofi, Sciarc GmbH, Sherborne Gibbs Limited and Tetris. Marc Evans: research support: Novo Nordisk and Takeda; speaker fees and honoraria: Boehringer Ingelheim, AstraZeneca and Menarini. Marc is also the Editor-in-Chief of Diabetes Therapy\u00a0and was not involved in the selection of peer reviewers for the manuscript not any of the subsequent editorial decisions. June James: no relevant disclosures. Naresh Kanumilli: honoraria speaker fees and travel grants: Boehringer Ingelheim, AstraZeneca, Novo Nordisk, Menarini, Novartis and Abbott. Nicola Milne: funding for provision of educational sessions, attendance at conferences and for attending advisory boards: Boehringer Ingelheim, Astra Zeneca, Lilly, Novo Nordisk, Sanofi, Napp, Abbott, Roche, Menarini and Dexcom. Adie Viljoen: research studies funded by, served as advisor to and received lecture honoraria and travel support: Amgen, AstraZeneca, Boehringer Ingelheim, Lilly, MSD, Menarini, Novo Nordisk, Pfizer, Regeneron, Sanofi Aventis and Tosoh. David C Wheeler: ongoing consultancy agreement with AstraZeneca; payments for trial-related activities: AstraZeneca, Eledon, Galderma, GSK, Janssen, Merck, ProKidney, Tricida; honoraria\/speaker fees: Astellas, Bayer, Boehringer Ingelheim, GSK, Gilead, Mundipharma, MSD, Pharmacosmos, Springer and Vifor. John PH Wilding: consultancy\/advisory board work contracted via the University of Liverpool (no personal payment): Altimmune, AstraZeneca, Boehringer Ingelheim, Lilly, Napp, Novo Nordisk, Menarini, Mundipharma, Pfizer, Rhythm Pharmaceuticals, Sanofi, Saniona, Tern, Shionogi & Ysopia; named grant holder (at University of Liverpool) for research grants for clinical trials from AstraZeneca and Novo Nordisk; lecture fees: AstraZeneca, Boehringer Ingelheim, Medscape, Napp, Novo Nordisk and Rhythm; past president of the World Obesity Federation, member of the Association for the Study of Obesity, Diabetes UK, EASD, ADA and Society for Endocrinology; National lead for the Metabolic and Endocrine Speciality Group of the NIHR Clinical Research Network (CRN) and local lead for North West Coast CRN.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based upon previously conducted studies and does not involve any new studies of human or animal subjects. Some authors were involved in studies discussed within the paper that included human subjects, all of which complied with the tenets of the Declaration of Helsinki and used protocols that had been approved by relevant Institutional Review Boards\/Ethics Committees and included patients who had provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}